Lymphoma in inflammatory bowel disease

Baseline risk and influence of immunomodulators

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There has been controversy over whether inflammatory bowel disease (IBD) patients are at increased risk of developing malignant lymphoma relative to the general population. Large population-based studies from several locales have shown that there is not an increased risk of lymphoma in IBD compared to the general population, with two exceptions. Some but not all referral- or hospital-based studies have suggested an increased baseline risk of lymphoma in IBD; however, these studies must be discounted because referral bias may have influenced the results. The bulk of the evidence suggests no increased baseline risk of lymphoma in IBD. Although several case series have detected a low frequency of lymphoma in IBD patients receiving purine analogues, one series reported a markedly increased risk among those treated with azathioprine, methotrexate and cyclosporin. Moreover, there are several reports of Epstein-Barr virus-positive lymphomas, which are likely related to immunosuppression, occurring in patients receiving these medications. Whether immunomodulatory medications are associated with an increased risk of lymphoma in IBD remains unclear.

Original languageEnglish (US)
Pages (from-to)45-49
Number of pages5
JournalResearch and Clinical Forums
Volume24
Issue number1
StatePublished - 2002

Fingerprint

Immunologic Factors
Inflammatory Bowel Diseases
Lymphoma
Referral and Consultation
Population
Azathioprine
Human Herpesvirus 4
Methotrexate
Immunosuppression
Cyclosporine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b0a6deb73ca5486a978aded35c191713,
title = "Lymphoma in inflammatory bowel disease: Baseline risk and influence of immunomodulators",
abstract = "There has been controversy over whether inflammatory bowel disease (IBD) patients are at increased risk of developing malignant lymphoma relative to the general population. Large population-based studies from several locales have shown that there is not an increased risk of lymphoma in IBD compared to the general population, with two exceptions. Some but not all referral- or hospital-based studies have suggested an increased baseline risk of lymphoma in IBD; however, these studies must be discounted because referral bias may have influenced the results. The bulk of the evidence suggests no increased baseline risk of lymphoma in IBD. Although several case series have detected a low frequency of lymphoma in IBD patients receiving purine analogues, one series reported a markedly increased risk among those treated with azathioprine, methotrexate and cyclosporin. Moreover, there are several reports of Epstein-Barr virus-positive lymphomas, which are likely related to immunosuppression, occurring in patients receiving these medications. Whether immunomodulatory medications are associated with an increased risk of lymphoma in IBD remains unclear.",
author = "{Loftus, Jr}, {Edward Vincent}",
year = "2002",
language = "English (US)",
volume = "24",
pages = "45--49",
journal = "Research and Clinical Forums",
issn = "0143-3083",
publisher = "Wells Medical Ltd",
number = "1",

}

TY - JOUR

T1 - Lymphoma in inflammatory bowel disease

T2 - Baseline risk and influence of immunomodulators

AU - Loftus, Jr, Edward Vincent

PY - 2002

Y1 - 2002

N2 - There has been controversy over whether inflammatory bowel disease (IBD) patients are at increased risk of developing malignant lymphoma relative to the general population. Large population-based studies from several locales have shown that there is not an increased risk of lymphoma in IBD compared to the general population, with two exceptions. Some but not all referral- or hospital-based studies have suggested an increased baseline risk of lymphoma in IBD; however, these studies must be discounted because referral bias may have influenced the results. The bulk of the evidence suggests no increased baseline risk of lymphoma in IBD. Although several case series have detected a low frequency of lymphoma in IBD patients receiving purine analogues, one series reported a markedly increased risk among those treated with azathioprine, methotrexate and cyclosporin. Moreover, there are several reports of Epstein-Barr virus-positive lymphomas, which are likely related to immunosuppression, occurring in patients receiving these medications. Whether immunomodulatory medications are associated with an increased risk of lymphoma in IBD remains unclear.

AB - There has been controversy over whether inflammatory bowel disease (IBD) patients are at increased risk of developing malignant lymphoma relative to the general population. Large population-based studies from several locales have shown that there is not an increased risk of lymphoma in IBD compared to the general population, with two exceptions. Some but not all referral- or hospital-based studies have suggested an increased baseline risk of lymphoma in IBD; however, these studies must be discounted because referral bias may have influenced the results. The bulk of the evidence suggests no increased baseline risk of lymphoma in IBD. Although several case series have detected a low frequency of lymphoma in IBD patients receiving purine analogues, one series reported a markedly increased risk among those treated with azathioprine, methotrexate and cyclosporin. Moreover, there are several reports of Epstein-Barr virus-positive lymphomas, which are likely related to immunosuppression, occurring in patients receiving these medications. Whether immunomodulatory medications are associated with an increased risk of lymphoma in IBD remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0036265274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036265274&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 45

EP - 49

JO - Research and Clinical Forums

JF - Research and Clinical Forums

SN - 0143-3083

IS - 1

ER -